Skip to content

Author

B. Gessner

10 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Vaccination in Pregnancy with the Bivalent Respiratory Syncytial Virus Vaccine Elicits Significant Specific IgA, IgG, and Secretory Antibody Titers in Human Milk.

BACKGROUND AND OBJECTIVES The RSVpreF vaccine, licensed for the prevention of respiratory syncytial virus (RSV)-associated lower respiratory tract disease in infants <6 months via maternal immunization, protects infants through transplacental-transferred antibodies. Additional benefits may be conferred via vaccine-indu...

Jessica E. Atwell, J. Deese, Mayte Suarez-Farinas et al. · 0 citations
Open access Nov 2026

Comparison of Respiratory Syncytial Virus Versus Influenza-Associated Acute Respiratory Illness Hospitalizations Among Adults in North America.

INTRODUCTION Respiratory syncytial virus (RSV) and influenza cause substantial acute respiratory illness (ARI) and may be difficult to distinguish clinically. We compared characteristics of adults hospitalized with ARI, diagnosed with RSV versus influenza, using standardized systematic testing. METHODS The North Amer...

N. Aliabadi, Hammad Ali, Qing Liu et al. · 0 citations
Review Open access Sep 2026

High Mortality in Adults With Community-Acquired Pneumonia Admitted to Hospitals in South Africa Before and During the COVID-19 Pandemic, Stratified by HIV Serostatus and Viral Load: Data From a Prospective Cohort Study (2019–2021)

In-hospital and postdischarge community-acquired pneumonia mortality remains high, particularly among PWH, regardless of virologic status, warranting urgent investigation of mitigation strategies.

N. Sabet, Firdaus Nabeemeeah, K. Otwombe et al. · 0 citations
Aug 2026

Bivalent RSV Prefusion F Vaccine to Prevent Hospitalizations in Adults.

BACKGROUND Respiratory syncytial virus (RSV) is an important cause of severe respiratory disease in adults, with the highest burden among older adults and individuals with chronic health conditions. The bivalent RSV prefusion F (RSVpreF) vaccine has been shown to prevent RSV-associated respiratory illness, but data fro...

M. Lassen, S. Christensen, M. Yafasov et al. · 1 citation
Open access Sep 2026

The Impact of Respiratory Syncytial Virus Undertesting on Estimates of Disease Burden and Vaccine Effectiveness in a Large Integrated Healthcare System

Precision of VE against RSV-related ARI ED/hospital admissions improved substantially with inclusion of salvage testing compared to SOC testing alone, suggesting that frequent standard-of-care RSV testing contributes to underestimated disease burden.

B. Ackerson, Brandon Chia, N. Aliabadi et al. · 0 citations
#protein folding Open access Oct 2026

RSV prefusion F vaccine effectiveness in older adults with immunosuppression: a prespecified analysis of the DAN-RSV trial.

In adults aged 60 years or older, RSVpreF vaccination reduced hospitalisations for RSV-related respiratory tract disease with no statistical evidence of effect modification by immunosuppression status; however, the study was not powered to exclude subgroup differences.

A. Reimer Jensen, M. H. Højbjerg Lassen, N. Johansen et al. · 0 citations
Open access Sep 2026

Evaluation of the effect of serotype on pneumococcal conjugate vaccine-induced immunity: an exploratory analysis of the PREVENTING PNEUMO 2 trial.

BACKGROUND Although evidence suggests some direct protection against Streptococcus pneumoniae serotype 3 (Spn3) from the 13-valent pneumococcal conjugate vaccine (PCV13), Spn3 remains a common cause of pneumococcal disease. We aimed to assess whether serotype-specific humoral immune responses to capsule polysaccharide...

P. Gonzalez-Dias, A. Gonçalves, J. Reiné et al. · 0 citations
Review

Dose-specific efficacy of Haemophilus influenzae type b conjugate vaccines : a systematic review and meta-analysis of controlled clinical trials

The meta-analysis provides robust estimates for use in decision-analytical models designed to predict the impact of Hib vaccine, and provides robust estimates for use in decision-analytical models designed to predict the impact of Hib vaccine.

U. Griffiths, A. Clark, B. Gessner et al. · 0 citations
Open access Aug 2026

Effects of attenuated influenza virus administration to young children on pneumococcal density and acquisition in UK families: a randomised controlled trial

Regression analyses showed that there was a 2·5-times increase in the odds of vaccinated children having increased pneumococcal density 14 days later, compared with that in unvaccinated children, and a 2·0-times increase in the odds of S pneumoniae acquisition in household members after administering LAIV.

J. Metz, George Qian, B. Morales-Aza et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.